Autopsy report · NCT04024384

Daratumumab as Maintenance After Peripheral Blood Stem Cell Transplantation From HLA-identical or Haploidentical Family Donor in the Treatment of Refractory or Relapsed Multiple Myeloma: a Phase 2 Trial

Cause of deathOther Automatic label, confidence 0.3, unverified. How labels are made.

“Promotor decision”

The sponsor’s own words in the registry.

Life of this trial

Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status: Withdrawn
Phase: Phase 2
Sponsor: Assistance Publique - Hôpitaux de Paris
Sponsor type: University, hospital or other
Conditions: Multiple Myeloma
Interventions: Daratumumab
Participants: 0
Sites: 1
Countries: France

Look deeper

The official registry record (the source of truth)
Record history: every change the sponsor made
Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.